Athersys, Inc. is a biotechnology company that aims to discover, develop, and commercialize innovative therapies to treat serious and life-threatening diseases. As part of their commitment to advancing the field of neuroscience, Athersys is set to participate in the American Society for Neural Therapy and Repair Annual Conference. This event brings together leading scientists, clinicians, and industry experts to share their latest research and breakthroughs in the field of neural therapy and repair. Athersys’ participation in this conference reflects its dedication to developing ground-breaking therapies that address the unmet medical needs in the neuroscience field.
Regenerative medicine company Athersys has announced that it will be participating in The American Society for Neural Therapy and Repair Annual Conference, taking place from April 27-30, 2023 in Clearwater, Florida. The event is aimed at basic and clinical neuroscientists with a focus on understanding how the nervous system functions and how it can be repaired in response to trauma or neurodegenerative disease. Dr. Sarah Busch, Vice President of Regenerative Medicine and Head of Business Development, has been invited to participate in the conference. Dr. Busch will be giving a talk on “MultiStem Cellular Therapy for Neurological Indications” on April 28th, and on the same day will participate in a discussion on “Career Retention and Development of Female Neuroscientists.” On April 29th, Dr Busch will co-chair the “Translating Treatments for Neural Injury & Disease” panel discussion. Athersys is excited to attend the conference and to share the progress made with MultiStem and engage with other experts in the field of neuroscience. Athersys’ MultiStem therapy has shown the ability to promote tissue repair and healing in a variety of ways and represents a unique “off-the-shelf” stem cell product that can be stored for years in frozen form and administered without tissue matching or the need for immune suppression. The company is developing MultiStem cell therapy product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications.
In addition, Athersys has forged strategic partnerships and a broad network of collaborations to advance its MultiStem cell therapy towards commercialization. The company encourages investors, media, and others interested in Athersys to review the information on their social media accounts, as it may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. MultiStem therapy has shown a consistent ability to promote tissue repair and healing in a range of therapeutic areas, and therefore could provide a meaningful benefit to patients suffering from serious diseases or conditions with unmet medical need. Athersys continues to work towards its mission of extending and enhancing the quality of human life through its innovative regenerative medicine products.
In conclusion, Athersys, Inc. is making significant strides in the field of regenerative medicine, and its participation in the American Society for Neural Therapy and Repair Annual Conference is a testament to its commitment to advancing the industry. With its innovative technology and talented team of scientists, Athersys is poised to make a positive impact on patients’ lives and revolutionize the field of medicine. As we eagerly await the future developments of this groundbreaking company, we look forward to seeing the ways that Athersys will continue to change the face of regenerative medicine.
